<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en" article-type="rapid-communication" dtd-version="2.3">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">molbank</journal-id>
      <journal-title>Molbank</journal-title>
      <abbrev-journal-title abbrev-type="publisher">Molbank</abbrev-journal-title>
      <abbrev-journal-title abbrev-type="pubmed">Molbank</abbrev-journal-title>
      <issn pub-type="epub">1422-8599</issn>
      <publisher>
        <publisher-name>MDPI</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.3390/M790</article-id>
      <article-id pub-id-type="publisher-id">molbank-2012-M790</article-id>
      <article-categories>
        <subj-group>
          <subject>Short Note</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>5-(<italic>tert</italic>-Butyldimethylsilyloxy)-1-(2-chloro-5,8-dimethoxyquinolin-3-yl)-3-methylenepentan-1-ol</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Bouarata</surname>
            <given-names>Linda</given-names>
          </name>
          <xref rid="af1-molbank-2012-M790" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tebbani</surname>
            <given-names>Dahmane</given-names>
          </name>
          <xref rid="af1-molbank-2012-M790" ref-type="aff">1</xref>
          <xref rid="c1-molbank-2012-M790" ref-type="corresp">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mosset</surname>
            <given-names>Paul</given-names>
          </name>
          <xref rid="af2-molbank-2012-M790" ref-type="aff">2</xref>
        </contrib>
      </contrib-group>
      <aff id="af1-molbank-2012-M790"><label>1</label>D&#xE9;partement de chimie, Facult&#xE9; des sciences, Universit&#xE9; de Constantine 1, Constantine 25000, Algeria</aff>
      <aff id="af2-molbank-2012-M790"><label>2</label>Universit&#xE9; de Rennes 1, Institut des Sciences Chimiques de Rennes, CNRS UMR 6226, Avenue du G&#xE9;n&#xE9;ral Leclerc, 35042 Rennes Cedex, France</aff>
      <author-notes>
        <corresp id="c1-molbank-2012-M790"><label>*</label>Author to whom correspondence should be addressed; E-Mail: <email>dtebbani2002@yahoo.fr</email>.</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>14</day>
        <month>12</month>
        <year>2012</year>
      </pub-date>
      <pub-date pub-type="collection">
        <month>12</month>
        <year>2012</year>
      </pub-date>
      <volume>2012</volume>
      <issue>4</issue>
      <elocation-id>M790</elocation-id>
      <history>
        <date date-type="received">
          <day>30</day>
          <month>10</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>04</day>
          <month>12</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2012 by the authors; licensee MDPI, Basel, Switzerland.</copyright-statement>
        <copyright-year>2012</copyright-year>
        <license>
          <p>This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).</p>
        </license>
      </permissions>
      <abstract>
        <p>Novel 5-(<italic>tert</italic>-butyldimethylsilyloxy)-1-(2-chloro-5,8-dimethoxyquinolin-3-yl)-3-methylenepentan-1-ol (<bold>7</bold>) was prepared via allylation of 2-chloro-5,8-dimethoxyquinoline-3-carbaldehyde (<bold>6</bold>) with functionalized allylic iodide as <italic>tert</italic>-butyl-(3-(iodomethyl)but-3-enyloxy)dimethylsilane (<bold>5</bold>), in the presence of metallic indium in anhydrous DMF as solvent at ambient temperature. The structure of the synthesized compound was assigned on the basis of elemental analysis and spectral data.</p>
      </abstract>
      <kwd-group>
        <kwd>functionalized allylic iodide</kwd>
        <kwd>allylation</kwd>
        <kwd>indium</kwd>
        <kwd>quinoline derivatives</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introduction</title>
      <p>Quinoline and its derivatives form an important class of organic compounds due to their structural chemistry and biological activities as antifungal [<xref ref-type="bibr" rid="B1-molbank-2012-M790">1</xref>,<xref ref-type="bibr" rid="B2-molbank-2012-M790">2</xref>], antibacterial [<xref ref-type="bibr" rid="B2-molbank-2012-M790">2</xref>,<xref ref-type="bibr" rid="B3-molbank-2012-M790">3</xref>,<xref ref-type="bibr" rid="B4-molbank-2012-M790">4</xref>,<xref ref-type="bibr" rid="B5-molbank-2012-M790">5</xref>,<xref ref-type="bibr" rid="B6-molbank-2012-M790">6</xref>,<xref ref-type="bibr" rid="B7-molbank-2012-M790">7</xref>], antiviral [<xref ref-type="bibr" rid="B3-molbank-2012-M790">3</xref>,<xref ref-type="bibr" rid="B8-molbank-2012-M790">8</xref>,<xref ref-type="bibr" rid="B9-molbank-2012-M790">9</xref>,<xref ref-type="bibr" rid="B10-molbank-2012-M790">10</xref>,<xref ref-type="bibr" rid="B11-molbank-2012-M790">11</xref>,<xref ref-type="bibr" rid="B12-molbank-2012-M790">12</xref>], and anticancer [<xref ref-type="bibr" rid="B9-molbank-2012-M790">9</xref>,<xref ref-type="bibr" rid="B13-molbank-2012-M790">13</xref>,<xref ref-type="bibr" rid="B14-molbank-2012-M790">14</xref>,<xref ref-type="bibr" rid="B15-molbank-2012-M790">15</xref>,<xref ref-type="bibr" rid="B16-molbank-2012-M790">16</xref>] properties. Compounds possessing the quinoline moiety exhibit significant activity against several diseases such as malaria [<xref ref-type="bibr" rid="B17-molbank-2012-M790">17</xref>], and cardiovascular pathologies [<xref ref-type="bibr" rid="B18-molbank-2012-M790">18</xref>,<xref ref-type="bibr" rid="B19-molbank-2012-M790">19</xref>]. In continuation to develop synthesis of compounds possessing biological activities, we report in this paper the synthesis of homoallylic alcohol <bold>7</bold> by allylation [<xref ref-type="bibr" rid="B20-molbank-2012-M790">20</xref>] of 2-chloro-5,8-dimethoxyquinoline-3-carbaldehyde (<bold>6</bold>) with functionalized allylic iodide <bold>5</bold> using metallic indium. The synthesized homoallylic alcohol <bold>7</bold> is an intermediate for the synthesis of heterocyclic compounds. Tetrahydrofurans and tetrahydropyrans are important moieties of natural biologically active compounds such as antibiotics (Monensine, Lasalocide A) and antimicrobial (Milbemycine, Avermectines). It was also found that spiroacetals obtained by allylation of cycloalkanones, are contained in many natural compounds produced by insects having pheromonal activity.</p>
    </sec>
    <sec>
      <title>Result and Discussion</title>
      <p>We have synthesized the allylic iodide <bold>5</bold> according to a known method [<xref ref-type="bibr" rid="B21-molbank-2012-M790">21</xref>] (<xref ref-type="scheme" rid="molbank-2012-M790-sch001">scheme 1</xref>), in three steps starting from dimethyl itaconate (<bold>1</bold>). The iodide was prepared in small quantities because it was unstable and was stored in darkness.</p>
	  <fig id="molbank-2012-M790-sch001" position="float">
        <object-id pub-id-type="pii">molbank-2012-M790-sch001_Scheme 1</object-id>
        <label>Scheme 1</label>
        <caption>
          <p>Synthesis of allylic iodide <bold>5</bold>.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2012-M790-sch001.tif"/>
      </fig>
      <p>We first studied the addition of allylic bromide <bold>3</bold> with aldehyde <bold>6</bold> in the presence of metallic indium in different solvents. Compared to acetonitrile, methanol and dichloromethane, DMF was found to be a good solvent. Allylic iodide <bold>5</bold> and bromide <bold>3</bold> were equally reactive. However, the reactivity of allylic chloride <bold>4</bold> was markedly diminished.</p>
	  <fig id="molbank-2012-M790-sch002" position="float">
        <object-id pub-id-type="pii">molbank-2012-M790-sch002_Scheme 2</object-id>
        <label>Scheme 2</label>
        <caption>
          <p>Synthesis of 5-(<italic>tert</italic>-butyldimethylsilyloxy)-1-(2-chloro-5,8-dimethoxyquinolin-3-yl)-3-methylenepentan-1-ol (<bold>7</bold>).</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2012-M790-sch002.tif"/>
      </fig>
    </sec>
    <sec sec-type="methods">
      <title>Experimental</title>
      <p>All reactions were carried out under nitrogen atmosphere. DMF was dried on BaO and distilled under reduced pressure and stored on molecular sieves 4&#xC5;. Progress of the reactions and purity of the compounds were monitored by thin layer chromatography (TLC) using ethyl acetate/<italic>n</italic>-hexane as eluting system on silica gel (60&#x2013;120 mesh), UV apparatus and anisaldehyde solution as visualizing agents.</p>
      <p><sup>1</sup>H (400 MHz) and <sup>13</sup>C (100 MHz) spectra were recorded on a Bruker FT-ARX 400 spectrometer in CDCl<sub>3</sub> using TMS as internal standard. The IR spectra were recorded on a Nicolet 205 FT spectrometer as KBr pellets. Elemental analysis was performed by the regional center of analysis of Rennes, CRMPO (Centre r&#xE9;gional de mesures physiques de l&#x2019;Ouest), Rennes, France.</p>
      <p>To a suspension of indium powder (345 mg, 3 mmol) in dry DMF (3 mL) was added allylic iodide <bold>5</bold> (977.7 mg, 3 mmol) in DMF (1 mL) and 2-chloro-5,8-dimethoxyquinoline-3-carbaldehyde (<bold>6</bold>) (503.0 mg, 2 mmol) in DMF (1 mL). An exothermic reaction occurred immediately, the mixture was stirred at room temperature for 1 h and the mixture was quenched by addition of diluted hydrochloric acid. The product was extracted with ether and purified by column chromatography on silica gel (petroleum ether/ethyl acetate 50:50) to afford homoallylic alcohol <bold>7</bold> as yellow oil.</p>
      <p>Yield: 0.76 g (84%).</p>
      <p>IR (KBr, cm<sup>&#x2212;1</sup>) &#x3BD; 3415 (OH), 1647 (C=C).</p>
      <p><sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) &#x3B4; 8.90 (s, 1H, H-C<sub>4</sub>), 7.04 (d, 1H, <italic>J</italic> = 8.6 Hz, H-C<sub>7</sub>), 6.83 (d, 1H, <italic>J</italic> = 8.6 Hz, H-C<sub>6</sub>), 5.27 (ddd, 1H, <italic>J</italic> = 9.9, 2.4, 2.3 Hz, C<underline>H</underline>OH), 5.10 (m, 1H, C=C<underline>H</underline><sub>2</sub>), 5.08 (broad ddd, 1H, <italic>J</italic> = 1.8, 1.6, 1.2 Hz, C=C<underline>H</underline><sub>2</sub>), 4.03 (s, 3H, OC<underline>H</underline><sub>3</sub>), 3.98 (s, 3H, OC<underline>H</underline><sub>3</sub>), 3.94&#x2013;3.83 (m, 2H, C<underline>H</underline><sub>2</sub>OSi), 3.39 (d, 1H, <italic>J</italic> = 2.4 Hz, O<underline>H</underline>), 2.86 (ddd, 1H, <italic>J</italic> = 14.0, 2.4, 1.4 Hz, C<underline>H</underline><sub>2</sub>CHOH), 2.44 (pseudo broad tt, 2H, <italic>J</italic> = 6.4, 1.0 Hz, C<underline>H</underline><sub>2</sub>CH<sub>2</sub>OSi), 2.20 (ddd, 1H, <italic>J</italic> = 14.0, 9.9, 0.5 Hz, C<underline>H</underline><sub>2</sub>CHOH), 0.92 (s, 9H, <italic>t</italic>-Bu), 0.10 (s, 6H, Si(C<underline>H</underline><sub>3</sub>)<sub>2</sub>).</p>
      <p><sup>13</sup>C-NMR (100 MHz, CDCl<sub>3</sub>) &#x3B4; 148.81 (C<sub>quat</sub>, C<sub>8</sub>), 148.40 (C<sub>quat</sub>, C<sub>5</sub>), 146.86 (C<sub>quat</sub>, C<sub>8a</sub>), 143.59 (C<sub>quat</sub>, <underline>C</underline>=CH<sub>2</sub>), 142.52 (C<sub>quat</sub>, C<sub>2</sub>), 135.87 (C<sub>quat</sub>, C<sub>3</sub>), 135.65 (<underline>C</underline>H, C<sub>4</sub>), 130.0 (<underline>C</underline>H, C<sub>7</sub>), 127.57 (C<sub>quat</sub>, C<sub>4a</sub>), 127.06 (<underline>C</underline>H, C<sub>6</sub>), 115.89 (C=<underline>C</underline>H<sub>2</sub>), 68.71 (<underline>C</underline>HOH), 62.44 (<underline>C</underline>H<sub>2</sub>OSi), 56.24 (O<underline>C</underline>H<sub>3</sub>), 55.98 (O<underline>C</underline>H<sub>3</sub>), 45.65 (<underline>C</underline>H<sub>2</sub>CHOH), 38.58 (<underline>C</underline>H<sub>2</sub>CH<sub>2</sub>OSi), 25.96 (3C, C(<underline>C</underline>H<sub>3</sub>)<sub>3</sub>), 18.42 (C<sub>quat</sub>, <underline>C</underline>(CH<sub>3</sub>)<sub>3</sub>), &#x2212;5.29 (Si-<underline>C</underline>H<sub>3</sub>), &#x2212;5.33 (Si-<underline>C</underline>H<sub>3</sub>).</p>
      <p>Elemental analysis: Calculated for C<sub>23</sub>H<sub>34</sub>ClNO<sub>4</sub>Si: C, 61.13%; H, 7.53%; O, 14.17%; found: C, 61.05%; H, 7.47%; O, 14.08.</p>
    </sec>
  </body>
  <back>
  <app-group>
    <app id="app1-molbank-2012-M790">
        <title>Supplementary materials</title>
        <supplementary-material id="molbank-2012-M790-s001" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2012-M790-s001-mod.mol">
		<label>Supplementary File 1</label>
		</supplementary-material>
        <supplementary-material id="molbank-2012-M790-s002" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="molbank-2012-M790-s001.mol">
		<label>Supplementary File 2</label>
		</supplementary-material>
        </app>
	</app-group>
    <ref-list>
      <title>References</title>
      <ref id="B1-molbank-2012-M790">
        <label>1.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Musiol</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Serda</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Hensel-Bielowka</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Polanski</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Quinoline-Based Antifungals</article-title>
          <source>Curr. Med. Chem.</source>
          <year>2010</year>
          <volume>17</volume>
          <fpage>1960</fpage>
          <lpage>1973</lpage>
          <pub-id pub-id-type="doi">10.2174/092986710791163966</pub-id>
          <pub-id pub-id-type="pmid">20377510</pub-id>
        </citation>
      </ref>
      <ref id="B2-molbank-2012-M790">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kumar</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Bawa</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Gupta</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Biological Activities of Quinoline Derivatives</article-title>
          <source>Mini Rev. Med. Chem.</source>
          <year>2009</year>
          <volume>9</volume>
          <fpage>1648</fpage>
          <lpage>1654</lpage>
          <pub-id pub-id-type="doi">10.2174/138955709791012247</pub-id>
          <pub-id pub-id-type="pmid">20088783</pub-id>
        </citation>
      </ref>
      <ref id="B3-molbank-2012-M790">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Richter</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Parolin</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Palumbo</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Palu</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Antiviral Properties of Quinolone-based Drugs</article-title>
          <source>Curr. Drug Targets Infect. Disord.</source>
          <year>2004</year>
          <volume>4</volume>
          <fpage>111</fpage>
          <lpage>116</lpage>
          <pub-id pub-id-type="doi">10.2174/1568005043340920</pub-id>
          <pub-id pub-id-type="pmid">15180459</pub-id>
        </citation>
      </ref>
      <ref id="B4-molbank-2012-M790">
        <label>4.</label>
        <citation citation-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Segev</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Rubinstein</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Future aspects [of quinoline antibacterials]</article-title>
          <source>Handbook of Experimental Pharmacology</source>
          <person-group person-group-type="editor">
            <name>
              <surname>Kuhlmann</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Dalhoff</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Zeiler</surname>
              <given-names>H.-J.</given-names>
            </name>
          </person-group>
          <publisher-name>Springer</publisher-name>
          <publisher-loc>Berlin, Germany</publisher-loc>
          <year>1998</year>
          <volume>Volume 127</volume>
          <fpage>454</fpage>
          <lpage>475</lpage>
        </citation>
      </ref>
      <ref id="B5-molbank-2012-M790">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rosen</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>6 The fluoroquinolone antibacterial agents</article-title>
          <source>Prog. Med. Chem.</source>
          <year>1990</year>
          <volume>27</volume>
          <fpage>235</fpage>
          <lpage>295</lpage>
          <pub-id pub-id-type="pmid">2217826</pub-id>
        </citation>
      </ref>
      <ref id="B6-molbank-2012-M790">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lontie</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Les nouvelles quinolones</article-title>
          <source>J. Pharm. Belg.</source>
          <year>1989</year>
          <volume>44</volume>
          <fpage>292</fpage>
          <lpage>301</lpage>
          <pub-id pub-id-type="pmid">2691640</pub-id>
        </citation>
      </ref>
      <ref id="B7-molbank-2012-M790">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fernandes</surname>
              <given-names>P.B.</given-names>
            </name>
            <name>
              <surname>Chu</surname>
              <given-names>D.T.W.</given-names>
            </name>
          </person-group>
          <article-title>Quinolone antibacterial agents</article-title>
          <source>Annu. Rep. Med. Chem.</source>
          <year>1988</year>
          <volume>23</volume>
          <fpage>133</fpage>
          <lpage>140</lpage>
        </citation>
      </ref>
      <ref id="B8-molbank-2012-M790">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaushik</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Gupta</surname>
              <given-names>S.P.</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>P.K.</given-names>
            </name>
          </person-group>
          <article-title>Design and development of anti-hepatitis B virus agents</article-title>
          <source>Curr. Med. Chem.</source>
          <year>2010</year>
          <volume>17</volume>
          <fpage>3377</fpage>
          <lpage>3392</lpage>
          <pub-id pub-id-type="doi">10.2174/092986710793176375</pub-id>
          <pub-id pub-id-type="pmid">20712567</pub-id>
        </citation>
      </ref>
      <ref id="B9-molbank-2012-M790">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Das</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Krishnaiah</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Venkateswarlu</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Das</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Camptothecins: Review on the bioactive natural products. Part XVIII. Some recent chemical studies</article-title>
          <source>Nat. Prod. Commun.</source>
          <year>2006</year>
          <volume>1</volume>
          <fpage>255</fpage>
          <lpage>263</lpage>
        </citation>
      </ref>
      <ref id="B10-molbank-2012-M790">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Okamoto</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Cujec</surname>
              <given-names>T.P.</given-names>
            </name>
            <name>
              <surname>Okamoto</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Peterlin</surname>
              <given-names>B.M.</given-names>
            </name>
            <name>
              <surname>Baba</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Okamoto</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Inhibition of the RNA-Dependent Transactivation and Replication of Human Immunodeficiency Virus Type 1 by a Fluoroquinoline Derivative K-37</article-title>
          <source>Virology</source>
          <year>2000</year>
          <volume>272</volume>
          <fpage>402</fpage>
          <lpage>408</lpage>
          <pub-id pub-id-type="doi">10.1006/viro.2000.0396</pub-id>
          <pub-id pub-id-type="pmid">10873784</pub-id>
        </citation>
      </ref>
      <ref id="B11-molbank-2012-M790">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baba</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Okamoto</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Makino</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kimura</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Ikeuchi</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Sakaguchi</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Okamoto</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives</article-title>
          <source>Antimicrob. Agents Chemother.</source>
          <year>1997</year>
          <volume>41</volume>
          <fpage>1250</fpage>
          <lpage>1255</lpage>
          <pub-id pub-id-type="pmid">9174179</pub-id>
        </citation>
      </ref>
      <ref id="B12-molbank-2012-M790">
        <label>12.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wentland</surname>
              <given-names>M.P.</given-names>
            </name>
            <name>
              <surname>Perni</surname>
              <given-names>R.B.</given-names>
            </name>
            <name>
              <surname>Dorff</surname>
              <given-names>P.H.</given-names>
            </name>
            <name>
              <surname>Brundage</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Castaldi</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Carlson</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>T.R.</given-names>
            </name>
            <name>
              <surname>Aldous</surname>
              <given-names>S.C.</given-names>
            </name>
            <name>
              <surname>Carabateas</surname>
              <given-names>P.M.</given-names>
            </name>
            <name>
              <surname>Bacon</surname>
              <given-names>E.R.</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Antiviral properties of 3-quinolinecarboxamides: A series of novel non-nucleoside antiherpetic agents</article-title>
          <source>Drug Des. Discov.</source>
          <year>1997</year>
          <volume>15</volume>
          <fpage>25</fpage>
          <lpage>38</lpage>
          <pub-id pub-id-type="pmid">9332829</pub-id>
        </citation>
      </ref>
      <ref id="B13-molbank-2012-M790">
        <label>13.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Solomon</surname>
              <given-names>V.R.</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Quinoline as a privileged scaffold in cancer drug discovery</article-title>
          <source>Curr. Med. Chem.</source>
          <year>2011</year>
          <volume>18</volume>
          <fpage>1488</fpage>
          <lpage>1508</lpage>
          <pub-id pub-id-type="doi">10.2174/092986711795328382</pub-id>
          <pub-id pub-id-type="pmid">21428893</pub-id>
        </citation>
      </ref>
      <ref id="B14-molbank-2012-M790">
        <label>14.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khan</surname>
              <given-names>M.T.H.</given-names>
            </name>
          </person-group>
          <article-title>Quinoline analogs as antiangiogenic agents and telomerase inhibitors</article-title>
          <source>Top. Heterocycl. Chem.</source>
          <year>2007</year>
          <volume>11</volume>
          <fpage>213</fpage>
          <lpage>229</lpage>
        </citation>
      </ref>
      <ref id="B15-molbank-2012-M790">
        <label>15.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Joseph</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Darro</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Behard</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Lesur</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Collignon</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Decaestecker</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Frydman</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Guillaumet</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Kiss</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>3-Aryl-2-Quinolone Derivatives: Synthesis and Characterization of <italic>In Vitro</italic> and <italic>In Vivo</italic> Antitumor Effects with Emphasis on a New Therapeutical Target Connected with Cell Migration</article-title>
          <source>J. Med. Chem.</source>
          <year>2002</year>
          <volume>45</volume>
          <fpage>2543</fpage>
          <lpage>2555</lpage>
          <pub-id pub-id-type="doi">10.1021/jm010978m</pub-id>
          <pub-id pub-id-type="pmid">12036363</pub-id>
        </citation>
      </ref>
      <ref id="B16-molbank-2012-M790">
        <label>16.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bergh</surname>
              <given-names>J.C.S.</given-names>
            </name>
            <name>
              <surname>Toetterman</surname>
              <given-names>T.H.</given-names>
            </name>
            <name>
              <surname>Termander</surname>
              <given-names>B.C.</given-names>
            </name>
            <name>
              <surname>Strandgarden</surname>
              <given-names>K.A.-M.P.</given-names>
            </name>
            <name>
              <surname>Gunnarsson</surname>
              <given-names>P.O.G.</given-names>
            </name>
            <name>
              <surname>Nilsson</surname>
              <given-names>B.I.</given-names>
            </name>
          </person-group>
          <article-title>The first clinical pilot study of roquinimex (Linomide) in cancer patients with special focus on immunological effects</article-title>
          <source>Cancer Invest.</source>
          <year>1997</year>
          <volume>15</volume>
          <fpage>204</fpage>
          <lpage>211</lpage>
          <pub-id pub-id-type="doi">10.3109/07357909709039716</pub-id>
          <pub-id pub-id-type="pmid">9171853</pub-id>
        </citation>
      </ref>
      <ref id="B17-molbank-2012-M790">
        <label>17.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaur</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Jain</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Reddy</surname>
              <given-names>R.P.</given-names>
            </name>
            <name>
              <surname>Jain</surname>
              <given-names>R.</given-names>
            </name>
          </person-group>
          <article-title>Quinolines and structurally related heterocycles as antimalarials</article-title>
          <source>Eur. J. Med. Chem.</source>
          <year>2010</year>
          <volume>45</volume>
          <fpage>3245</fpage>
          <lpage>3264</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ejmech.2010.04.011</pub-id>
          <pub-id pub-id-type="pmid">20466465</pub-id>
        </citation>
      </ref>
      <ref id="B18-molbank-2012-M790">
        <label>18.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feldman</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Strobeck</surname>
              <given-names>J.E.</given-names>
            </name>
          </person-group>
          <article-title>Quinolinone derivatives in the management of congestive heart failure</article-title>
          <source>Coronary Artery Dis.</source>
          <year>1994</year>
          <volume>5</volume>
          <fpage>107</fpage>
          <lpage>111</lpage>
          <pub-id pub-id-type="doi">10.1097/00019501-199402000-00003</pub-id>
        </citation>
      </ref>
      <ref id="B19-molbank-2012-M790">
        <label>19.</label>
        <citation citation-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Javed</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>N.R.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and biological activity of quinoline analogues in cardiovascular disease</article-title>
          <source>Pharmacological Aspects of Cardiovascular Medicine</source>
          <person-group person-group-type="editor">
            <name>
              <surname>Javed</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <publisher-name>Research Signpost</publisher-name>
          <publisher-loc>Trivandrum, India</publisher-loc>
          <year>2002</year>
          <fpage>55</fpage>
          <lpage>83</lpage>
        </citation>
      </ref>
      <ref id="B20-molbank-2012-M790">
        <label>20.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Araki</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ito</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Butsugan</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Indium in organic synthesis: Indium-mediated allylation of carbonyl compounds</article-title>
          <source>J. Org. Chem.</source>
          <year>1988</year>
          <volume>53</volume>
          <fpage>1831</fpage>
          <lpage>1833</lpage>
          <pub-id pub-id-type="doi">10.1021/jo00243a052</pub-id>
        </citation>
      </ref>
      <ref id="B21-molbank-2012-M790">
        <label>21.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hughes</surname>
              <given-names>R.C.</given-names>
            </name>
            <name>
              <surname>Dvorak</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Meyers</surname>
              <given-names>A.I.</given-names>
            </name>
          </person-group>
          <article-title>An Asymmetric Approach to Spirocylic Systems: A Formal Synthesis of Zizaene</article-title>
          <source>J. Org. Chem.</source>
          <year>2001</year>
          <volume>66</volume>
          <fpage>5545</fpage>
          <lpage>5551</lpage>
          <pub-id pub-id-type="doi">10.1021/jo010439p</pub-id>
          <pub-id pub-id-type="pmid">11485481</pub-id>
        </citation>
      </ref>
    </ref-list>
   </back>
</article>
